بررسی فرآیند حمایت حقوقی از اطلاعات بالینی و آزمایشگاهی داروها در حقوق ایران، اتحادیه اروپا و ایالات متحده آمریکا

One of the most important new evidence of intellectual property that had always plenty of differences behind it regarding the protection or non-protection is the new medicine laboratory information that is presented to the competent state authority for consideration and registry. The original purpose of intellectual property is to protect all property that derives from human intellectual leaking. The medicine laboratory information or the same information concerning the quality, security and effectiveness of medicines is a new intellectual property group that whose protection in recent decades has been considered by the legal scholars. This group of Intellectual property is the valuable information that is the result of round the clock efforts of pharmacy area specialists in the laboratories and are deposited in the hands of registration authority until after obtaining the quality, security and effectiveness to acquire marketing and production. Although there are differences regarding the principle of protection of this information, but the prevailing and accepted view is to protect these new intellectual properties. However, those who accepted the principle of protection have different views on the type of applicable protection system to laboratory information. Some accepted the system of trade secrets, some accepted the system of illegal competition and some others accepted the special protection system. The present article believes in protection in the framework of special protection system. Please cite this article as: Mafi H, Shadman F. A Review of Legal Protection Process of Clinical and Laboratory Information in the Law of Iran, the European ::union:: and the United States of America. Iran J Med Law 2018; 11(43): 69-91.